A SARS-CoV-2 vaccine is a preparation that teaches your immune system to recognize and fight the virus responsible for COVID-19, without exposing you to the actual infection. Most versions work by presenting your body with a single viral protein, the spike, so your immune cells learn to attack it on sight. The specific delivery method varies: some vaccines use synthetic messenger RNA, others rely on a harmless carrier virus, and still others supply the spike protein directly. What they share is a common goal of priming both antibodies and immune cells to respond quickly if the real virus shows up.
Why the Spike Protein Is the Target
The SARS-CoV-2 virus is studded with spike glycoproteins that jut out from its surface. These spikes are what the virus uses to latch onto human cells and force its way inside. The specific part of the spike that grabs onto your cells is called the receptor-binding domain, and it has become central to both diagnostic testing and vaccine design.1PubMed. Recombinant expression and improved refolding of the SARS-CoV-2 spike receptor-binding domain in Escherichia coli By training your immune system to recognize the spike, vaccines effectively block the virus’s main tool for infection.
There is a catch, though. The spike protein naturally shapeshifts. Before the virus fuses with a human cell, the spike sits in what researchers call its “prefusion” shape. After fusion, it collapses into a different form. The prefusion shape is the one that best reveals the spots where antibodies can bind and neutralize the virus. So vaccine designers needed to lock the spike in that prefusion form. They did this by introducing small changes, specifically proline substitutions, into the protein’s structure. The original approach used two proline substitutions, and this became the basis for the first authorized mRNA vaccines.2Biota : Jurnal Ilmiah Ilmu-Ilmu Hayati. mRNA Vaccine Design Modifications and Their Implications for Next-Generation Vaccines: Lessons from COVID-19
A further-refined version called HexaPro used six proline substitutions instead of two. This yielded roughly ten times more protein during manufacturing and made the resulting molecule more resilient to heat, room-temperature storage, and repeated freeze-thaw cycles.3PubMed Central. Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes In animal studies, the HexaPro version triggered stronger antibody responses and neutralized multiple variants of concern about two to four times better than the original two-proline design. It also prompted a more robust cellular immune response.4PubMed Central. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern These kinds of protein-engineering refinements illustrate how vaccine development is not just about choosing the right target but also about presenting that target in the most useful shape.
How mRNA Vaccines Deliver the Instructions
The mRNA vaccines from Pfizer-BioNTech and Moderna became the most widely used COVID-19 vaccines globally. Instead of giving you the spike protein itself, they deliver a snippet of genetic instructions, messenger RNA, that tells your own cells to manufacture the spike temporarily. Your cells read the mRNA, produce the spike protein, display pieces of it on their surfaces, and your immune system mounts a response against it. The mRNA degrades within days and never enters the cell nucleus or alters your DNA.
Naked mRNA would be destroyed almost instantly in the bloodstream by enzymes. To protect it, the mRNA is wrapped in tiny fat bubbles called lipid nanoparticles. These nanoparticles shield the mRNA from degradation and help it slip into your cells by fusing with cell membranes. Once inside a cell, the nanoparticle gets trapped in a compartment called an endosome, and a small fraction of the mRNA escapes from there into the cell’s main workspace, where it can be read and translated into protein.5Nature Reviews Materials. Lipid nanoparticles for mRNA delivery
The mRNA itself was also chemically tweaked for better performance. Unmodified mRNA triggers alarm signals in your cells because immune sensors mistake it for viral genetic material, which would reduce the amount of spike protein your cells actually produce. By swapping in modified building blocks, particularly modified versions of the nucleoside uridine, vaccine designers prevented those alarm sensors from recognizing the mRNA, allowing cells to translate it into much higher quantities of the spike protein.6Nature Reviews Drug Discovery. mRNA vaccines for infectious diseases: principles, delivery and clinical translation This nucleoside modification was one of the breakthroughs that made mRNA vaccines practical and is part of what earned Katalin Karikó and Drew Weissman their Nobel Prize.
Viral Vector Vaccines
A different approach, used by the Oxford-AstraZeneca and Johnson & Johnson vaccines, relies on a harmless adenovirus to carry the genetic instructions for the spike protein into your cells. The adenovirus has been modified so it cannot replicate, meaning it delivers its cargo but does not cause an infection. Once inside your cells, the DNA instructions are read and converted into mRNA, which is then translated into spike protein, triggering an immune response.
One concern that surfaced early was whether viral vector DNA could integrate into human chromosomes. Researchers who examined this question concluded that integration of adenoviral vector DNA would be a rare chance event whose frequency and long-term consequences could not be assessed with certainty.7PubMed Central. Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome – Are Adenoviral Genes Expressed in Vector-based Vaccines? In practice, hundreds of millions of doses were administered without evidence of this becoming a clinically meaningful problem. Viral vector vaccines had the practical advantage of being storable at ordinary refrigerator temperatures, unlike the early mRNA formulations that required ultra-cold freezers.
Interest in viral vector platforms for COVID-19 largely waned after rare but serious blood-clotting events were associated with some adenoviral vaccines, leading several countries to restrict their use. The mRNA and protein subunit platforms took over most of the remaining demand. Still, viral vector technology remains important for other diseases and for regions where cold-chain logistics are limited.
Protein Subunit Vaccines
Protein subunit vaccines take the most traditional approach. Rather than instructing your cells to make the spike, they deliver the finished prefusion spike protein directly, along with an adjuvant, a substance that amplifies the immune response. The Novavax vaccine (NVX-CoV2373) is the best-known example. It pairs prefusion-stabilized spike protein with a saponin-based adjuvant called Matrix-M. In clinical trials, it demonstrated about 90% efficacy against SARS-CoV-2 infection, comparable to the mRNA vaccines.8Nature (npj Vaccines). Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2
The adjuvant component does important work at the injection site. Matrix-M triggers the arrival of innate immune cells, including neutrophils and other first-responder cells, to the muscle where the vaccine was injected and to nearby lymph nodes. This localized immune activation helps the adaptive immune system, the branch that creates targeted antibodies and memory cells, get a stronger start. Importantly, this activation stays mostly local rather than causing widespread inflammation throughout the body.8Nature (npj Vaccines). Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2
Some people who were hesitant about mRNA technology preferred protein subunit vaccines because the underlying approach, delivering a purified protein plus an adjuvant, has been used in other vaccines for decades. The trade-off was slower manufacturing timelines, which meant Novavax reached the market well after the mRNA options.
What Happens Inside Your Body After Vaccination
Regardless of the platform, the immune response that follows vaccination involves two major arms working together. The first is the antibody response. Once your immune system encounters the spike protein, specialized B cells begin producing antibodies that can recognize it. Some of these antibodies are neutralizing, meaning they physically block the spike from attaching to your cells. Germinal centers, specialized structures that form inside your lymph nodes, are where B cells undergo a kind of training camp: they mutate their antibody genes slightly, and the versions that bind the spike most tightly get selected and multiplied.9PubMed Central. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza This germinal center activity is critical for producing high-quality, long-lasting antibodies.
The second arm is the T cell response. CD4 T cells (helper cells) coordinate the broader immune effort, while CD8 T cells (killer cells) can directly destroy cells that have been infected by the virus. In animal studies, when antibodies alone were insufficient to neutralize a variant, memory CD4 and properly supported CD8 T cells still provided protection against infection without causing harmful lung inflammation.10PubMed Central. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants This is a key reason why vaccinated people who do catch a variant often have milder illness even when their antibody levels have dropped: their T cells pick up the slack.
Over time, the initial burst of antibodies fades, but the immune system retains a pool of memory B cells and memory T cells that can ramp up quickly if reexposed. Research tracking people for three years after the pandemic’s onset found that both vaccinated and previously infected individuals maintained a substantial pool of spike-reactive memory B cells. Having this memory B cell reservoir was associated with fewer breakthrough infections.11PubMed. Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic
Why Variants Complicated the Picture
The original vaccines were designed around the ancestral SARS-CoV-2 strain. As the virus evolved, mutations accumulated in the spike protein, especially in the receptor-binding domain that antibodies target. By the time the Omicron variant (B.1.1.529) appeared, its spike carried so many changes that it was markedly resistant to neutralization by antibodies from both vaccinated and previously infected people. Even sera from individuals who had received a booster dose of an mRNA vaccine showed substantially diminished neutralizing activity against Omicron. Out of 19 monoclonal antibodies tested, covering every known binding site on the spike, 17 had their activity either abolished or significantly impaired.12Nature. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
This level of antibody escape is why booster doses and updated vaccine formulations became necessary. Neutralizing antibody levels serve as a key correlate of protection. Research on the Omicron BA.1 and BA.2 subvariants found that achieving 50% or 80% protection from infection required a certain threshold of antibodies matched to the circulating strain; using antibodies raised against the original D614G strain required more than three times the titer to reach the same protection level.13Nature Communications. Variant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections In other words, the closer the match between your antibodies and the circulating virus, the less antibody you need to stay protected. A separate household study during the Delta wave estimated that IgG concentrations above 500 BAU/mL and neutralizing antibody titers of 1024 or higher were thresholds associated with protection against Delta infection.14The Lancet Microbe. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study
Updated Vaccines and Strain Selection
Because the virus keeps evolving, regulatory agencies now recommend periodic updates to the vaccine strain, similar to the annual process for influenza vaccines. The mRNA platform is particularly well suited for this: changing the vaccine means swapping in a new mRNA sequence coding for the updated spike, while the lipid nanoparticle delivery system stays the same. Manufacturing can be scaled up relatively quickly compared to protein-based or viral vector approaches.
An XBB.1.5-targeted monovalent booster, for example, not only raised antibodies against XBB.1.5 itself by roughly 27-fold but also boosted responses against emerging subvariants like HV.1, HK.3, and JN.1 by 13- to 27-fold in previously uninfected individuals.15PubMed Central. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1 Later work comparing JN.1 and KP.2 mRNA vaccine formulations found that both boosted neutralizing antibodies against a range of current circulating variants, and the minor antigenic differences between the two strains did not meaningfully change the breadth of the response. The researchers concluded that vaccine strain updates may not be necessary for closely related variants in the absence of a major antigenic shift.16PubMed Central. Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants
The T cell side of the equation is also relevant here. While antibodies are the first line of defense that can prevent infection outright, T cell recognition is generally more forgiving of mutations. A study comparing booster types found that mRNA boosters, whether monovalent or bivalent, induced T cell responses against XBB variants, while an inactivated whole-virus booster did not achieve the same effect for antibodies against those variants.17PubMed. Determination of T cell response against XBB variants in adults who received either monovalent wild-type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster The practical lesson is that different vaccine platforms do not perform identically when it comes to keeping pace with viral evolution.
Hybrid Immunity and Why Infection Plus Vaccination Outperforms Either Alone
People who have been both vaccinated and infected with SARS-CoV-2 tend to develop what is called hybrid immunity, and it provides notably broader and more durable protection than either vaccination or infection alone. This happens because each exposure (vaccine and virus) stimulates the immune system somewhat differently, and the combined effect matures the antibody response in ways a single type of exposure cannot.
At the molecular level, antibodies originally raised by vaccination can gain neutralization breadth and potency after a breakthrough infection. One well-characterized antibody, SC27, was initially induced by vaccination, but following a breakthrough infection it expanded its ability to neutralize multiple SARS-CoV-2 variants and even some animal coronaviruses, with greatly increased binding affinity to a protective spot on the spike.18PubMed Central. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination The study noted that binding patterns like SC27’s are common in people with hybrid immunity, not just a fluke in one individual.
Beyond antibodies, hybrid immunity appears to activate parts of the innate immune system that vaccination alone does not. Research comparing hybrid-immune individuals to vaccine-only groups found that while hybrid immunity yielded higher neutralizing antibody levels, antibody levels alone did not fully predict who would get a breakthrough infection. Instead, enhanced production of the signaling molecule IL-8 and increased neutrophil activation appeared to contribute an additional layer of protection against Omicron variants.19PubMed Central. Hybrid immunity from bivalent vaccination and prior infection enhances humoral and innate protection against Omicron XBB.1.16 and EG.5.1.1 variants in Japan This finding is a reminder that protection against COVID-19 is not simply about antibody numbers.
The Mucosal Gap and Intranasal Vaccines
One widely discussed limitation of all currently injected COVID-19 vaccines is that they generate strong immune responses in the blood but relatively weak ones at the mucosal surfaces of the nose and throat, which is where the virus first lands. After two doses of an mRNA vaccine, about 94% of participants had anti-spike IgG antibodies in their saliva, but only about 41% had detectable salivary IgA, the antibody class most active at mucosal surfaces. IgA levels were significantly lower than those seen in people recovering from natural COVID-19 infection.20Mucosal Immunology. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection This gap helps explain why vaccinated people can still get infected in their upper airways, even when they are well protected against severe disease.
Intranasal vaccines, delivered as sprays or drops into the nose, aim to close this gap. By presenting antigens directly to the mucosal immune system, they can stimulate secretory IgA production and the development of tissue-resident memory cells right where the virus enters. In animal studies, intranasal vaccines significantly reduced viral replication and transmission by generating localized mucosal immunity alongside a systemic immune response.21Vaccine. A review of currently licensed mucosal COVID-19 vaccines Several intranasal COVID-19 vaccines have been licensed in countries including China and India, and early clinical investigations suggest they can elicit mucosal IgA against both matched and related viral strains.22PubMed Central. Detection of Anti‐SARS‐CoV‐2 Mucosal Immunoglobulin A in Clinical Saliva Samples After a Dose of Novavax COVID‐19 Vaccine
Some researchers are working on combination intranasal vaccines targeting both COVID-19 and influenza simultaneously. In mouse studies, one such vaccine using an adenoviral vector induced systemic IgG, mucosal IgA, neutralizing antibodies, and memory T cells, and it protected the animals from both an Omicron subvariant and pandemic influenza.9PubMed Central. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza Whether these results translate well into human populations is still an open question, but the appeal is obvious: a single nasal spray that addresses two respiratory threats and does not require a needle.
Vaccine-Associated Myocarditis
The most prominent safety signal associated with mRNA COVID-19 vaccines has been myocarditis, an inflammation of the heart muscle, occurring primarily in young men after the second dose. The proposed mechanisms involve both the innate and adaptive immune responses directed against the spike protein itself, but also recognition of the mRNA component by the immune system. The male predominance mirrors the pattern seen in viral myocarditis and may relate to sex hormones: testosterone tends to activate certain inflammatory T cell pathways, while estrogen dampens them, potentially explaining why young men in particular are susceptible.23PubMed Central. Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective
Most vaccine-associated myocarditis cases have been mild, with symptoms resolving within days to weeks, and the risk is substantially lower than the risk of myocarditis from a COVID-19 infection itself. The recognition of this side effect led to adjustments in some countries’ vaccination recommendations for younger males, including longer intervals between doses and, in some cases, preference for the Pfizer vaccine over Moderna for that age group because of Moderna’s higher mRNA dose.
How Prior Coronavirus Vaccine Research Laid the Groundwork
The speed at which COVID-19 vaccines were developed gave some people the impression that corners were cut. In reality, the vaccine platforms drew heavily on years of prior work against related coronaviruses. Researchers had been studying vaccine strategies against SARS-CoV (the virus behind the 2003 SARS outbreak) and MERS-CoV (which emerged in 2012) for over a decade. Each of those efforts tested different immunization strategies, including whole inactivated virus, live attenuated virus, viral vectors, DNA, protein subunits, and early-stage mRNA, and documented the pros and cons of each approach.24PubMed Central. Coronavirus vaccine development: from SARS and MERS to COVID-19 When SARS-CoV-2 appeared and its genome was published in January 2020, researchers already knew that the spike protein was the right target and that stabilizing it in its prefusion shape was important. The head start was scientific, not regulatory. The clinical trials themselves enrolled tens of thousands of participants and followed standard safety monitoring protocols.
The prefusion-stabilization technique that made the COVID-19 spike vaccines possible was actually first demonstrated with a different virus, RSV (respiratory syncytial virus), by some of the same structural biologists at the National Institutes of Health. That same two-proline substitution strategy was adapted almost immediately to the SARS-CoV-2 spike once its structure was solved. The speed of that translation, from seeing the new virus’s protein structure to having a stabilized vaccine antigen, was weeks rather than years precisely because the underlying method had already been validated.